Jushi Holdings Inc.

JUSH ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Income Statement
Annual Quarterly

Income Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
Revenue $262.9M $257.5M $269.4M $284.3M $209.3M $80.8M
Cost of Revenue $148.9M $139.2M $153.2M $188.8M $125.9M $42.4M
Gross Profit $114.0M $118.3M $116.2M $95.5M $83.4M $38.3M
Gross Margin 43.4% 45.9% 43.1% 33.6% 39.8% 47.5%
Operating Expenses
Research & Development — — — — — —
SG&A Expense $109.1M $107.0M $110.5M $156.2M $112.8M $54.9M
Operating Income $4.9M $10.9M $-2.8M $-220.3M $-35.8M $-16.6M
Operating Margin 1.8% 4.2% -1.0% -77.5% -17.1% -20.5%
Interest Expense — — $37.1M $45.7M $30.9M $15.6M
Pretax Income — — — — — —
Income Tax Expense $35.0M $31.6M $31.8M $8.4M $29.6M $10.6M
Net Income $-68.6M $-48.8M $-65.1M $-202.3M $20.3M $-210.6M
Net Margin -26.1% -18.9% -24.2% -71.2% 9.7% -260.7%
EPS (Basic) $-0.35 $-0.25 $-0.33 $-1.06 $0.12 $-1.94
EPS (Diluted) $-0.35 $-0.25 $-0.33 $-1.44 $-0.42 $-1.94
Shares Outstanding (Basic) 195.2M 195.2M 194.8M 190.0M 170.3M 108.5M
Shares Outstanding (Diluted) 195.2M 195.2M 194.8M 204.2M 201.6M 108.5M
Dividends Per Share — — — — — —